Estrogen receptor β1 and the β2/βcx isoforms in nonneoplastic endometrium and in endometrioid carcinoma

被引:28
作者
Chakravarty, D.
Srinivasan, R.
Ghosh, S.
Gopalan, S.
Rajwanshi, A.
Majumdar, S.
机构
[1] Postgrad Inst Med Educ & Res, Dept Cytol & Gynecol Pathol, Chandigarh 160012, India
[2] Postgrad Inst Med Educ & Res, Canc Biol Lab, Chandigarh 160012, India
[3] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India
[4] Postgrad Inst Med Educ & Res, Dept Obstet & Gynecol, Chandigarh 160012, India
关键词
beta cx; carcinoma; endometrioid; endometrium; estrogen receptor beta 1; estrogen receptor beta 2;
D O I
10.1111/j.1525-1438.2006.00851.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Estrogen receptor beta (ER beta) has five carboxyl-terminal (C-terminal) isoforms derived from alternative splicing. ER beta 1 is the wild-type receptor whereas ER beta 2/beta cx lacks the activation function (AF)-2 core essential for ligand-dependent transcriptional activation and so behaves as a dominant-negative receptor affecting the function of ER alpha. The objective of this study was to analyze the expression of ER beta 1 and ER beta 2/beta cx isoforms in nonneoplastic endometrium and endometrioid carcinoma. The study was conducted on samples of 22 proliferative endometrium, 15 secretory endometrium, 20 simple hyperplasia (without atypia), and 26 endometrioid carcinomas. The transcript and protein levels were determined by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry, respectively. For the detection of ER beta 2/beta cx protein, a polyclonal antibody was raised to its unique C-terminus, characterized, and used in immunohistochemistry. The two ER beta isoforms are expressed in the proliferative and secretory phase endometrium with no significant change in their relative levels. The levels of the ER beta 1 isoform. were lower as compared to the levels of ER beta 2 in all the groups studied. Expression of ER beta 2/beta cx was decreased in endometrioid carcinoma as compared to proliferative endometrium (P < 0.01). A significant decrease of the ER beta 2/ER beta cx transcript was observed with higher grade tumors (P = 0.041). Progesterone receptor (PR) expression was not influenced by either of the ER beta isoforms which was observed by logistic regression analysis in all the groups. The coexpression of ER beta 2/beta cx with ER alpha did not affect PR levels (logistic regression analysis). Thus, we conclude in the human endometrium, there is significant ER beta 2/beta cx isoform expression and alterations in its levels could be involved in endometrial cancer progression.
引用
收藏
页码:905 / 913
页数:9
相关论文
共 22 条
  • [1] [Anonymous], 1994, HISTOLOGICAL TYPING
  • [2] Loss of ERβ expression as a common step in estrogen-dependent tumor progression
    Bardin, A
    Boulle, N
    Lazennec, G
    Vignon, F
    Pujol, P
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (03) : 537 - 551
  • [3] Wild-type estrogen receptor (ERβ1) and the splice variant (ER/βcx/,β2) are both expressed within the human endometrium throughout the normal menstrual cycle
    Critchley, HD
    Henderson, TA
    Kelly, RW
    Scobie, GS
    Evans, LR
    Groome, NP
    Saunders, PTK
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) : 5265 - 5273
  • [4] IDENTIFICATION OF A CONSERVED REGION REQUIRED FOR HORMONE DEPENDENT TRANSCRIPTIONAL ACTIVATION BY STEROID-HORMONE RECEPTORS
    DANIELIAN, PS
    WHITE, R
    LEES, JA
    PARKER, MG
    [J]. EMBO JOURNAL, 1992, 11 (03) : 1025 - 1033
  • [5] ACTIVATION FUNCTION-2 (AF-2) OF RETINOIC ACID RECEPTOR AND 9-CIS RETINOIC ACID RECEPTOR - PRESENCE OF A CONSERVED AUTONOMOUS CONSTITUTIVE ACTIVATING DOMAIN AND INFLUENCE OF THE NATURE OF THE RESPONSE ELEMENT ON AF-2 ACTIVITY
    DURAND, B
    SAUNDERS, M
    GAUDON, C
    ROY, B
    LOSSON, R
    CHAMBON, P
    [J]. EMBO JOURNAL, 1994, 13 (22) : 5370 - 5382
  • [6] Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern
    Enmark, E
    Pelto-Huikko, M
    Grandien, K
    Lagercrantz, S
    Lagercrantz, J
    Fried, G
    Nordenskjöld, M
    Gustafsson, JÅ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (12) : 4258 - 4265
  • [7] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481
  • [8] Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression
    Krikun, G
    Schatz, F
    Taylor, R
    Critchley, HOD
    Rogers, PAW
    Huang, J
    Lockwood, CJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) : 1812 - 1818
  • [9] KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO
  • [10] 2-X